

Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022

<https://marketpublishers.com/r/PB44E23F109EN.html>

Date: June 2012

Pages: 185

Price: US\$ 2,635.00 (Single User License)

ID: PB44E23F109EN

Abstracts

Report Details

Antibacterial medicines - discover performance and commercial prospects of companies

How are leading companies in the antibacterial drugs market performing? Visiongain's new report gives you data, analyses and revenue predictions for antibacterial manufacturers.

See how top companies worldwide are performing and where they are heading. You assess their technologies, products and commercial prospects to 2022.

In our study you find analytical profiles for leading antibiotics producers. The work shows product ranges, R&D and sales prospects, with revenue forecasts from 2012 to 2022:

Pfizer

GSK

Merck & Co.

Novartis

Bayer

J&J

Cubist Pharmaceuticals

AstraZeneca

Abbott Laboratories

Medicis

Coverage of 10 other leading manufacturers and four top emerging companies.

You see how antibacterial drug producers compare, discovering how they can compete from 2012. You also find out what will stimulate and restrain business for companies.

The report covers leading pharmaceutical players, specialty companies and emerging organisations. Also, you find companies grouped by region of origin:

The US

Europe

Japan.

Our investigation gives you business research and analysis, including revenue forecasts at world market, submarket and company level to 2022. You find commercial data, predictions, and analyses for leading organisations, their industry and their market area.

Antibacterial drug producers: commercial outlook from 2012

Where is the antibiotics market heading? Many opportunities exist in that industry and market, particularly with the development of new classes of antibacterial drug. In particular, treatments targeting *C. difficile* and MRSA infections will make a difference to 2022.

Patent expiries will challenge antibiotic manufacturers throughout this decade, with generic pharmaceutical sales prominent and growing. Companies will use product

lifecycle management to reduce declines of brands and stimulate their sales, our analysis shows.

What about product launches, new drug classes and expanded indications? The antibacterial R&D pipeline has limitations but holds promise. You find out how leading companies can contribute to our predicted growth and renewal of the market to 2022.

In 2012, more than 50 product candidates are in clinical trials. There are many opportunities for collaborations and in-licensing. Many under-met treatment needs exist.

Which companies are best placed to harness opportunities in the discovery, development, manufacturing and marketing of antibacterial medicines? Our study shows you and explains.

Company analyses, revenue forecasts, R&D and discussions of industry prospects

In visiongain's report you find historical revenues, sales predictions, growth rates and market breakdowns. Also, you see discussions of companies, product portfolios, R&D, commercial news and revenue potentials. You receive 95 tables and 66 charts.

Ten ways Top 20 Antibacterial Drug Manufacturers 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:

Assess 20 leading antibacterial drug manufacturers, discovering their activities and outlooks from 2012

Discover overall world market and submarket revenue forecasts to 2022

Receive analyses of leading companies, seeing revenue forecasts to 2022

View a comparative analysis of trends among antibacterial manufacturers

Find existing revenues and operational data for leading companies

Review pipeline developments, assessing R&D trends and potential

Analyse recent licensing deals and acquisitions

Investigate competition and opportunities influencing sales

Review prospects for emerging companies and antimicrobial specialists

Find out what will stimulate and restrain the industry and market from 2012.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Gain research and analysis on antibacterial drug producers now

Our study is for everybody needing industry and market analyses of antibacterial drug developers and manufacturers. You find data, trends and predictions there. Please order that report now.

Contents

1. EXECUTIVE SUMMARY

- 1.1 Leading Antibacterial Drug Manufacturers: Overview of Findings
- 1.2 Chapter Breakdown
- 1.3 Research and Analysis Methods
- 1.4 Scope of this Report
 - 1.4.1 Drugs Considered for this Report
 - 1.4.1.1 Ophthalmic and Dermatologic Antibacterials
 - 1.4.2 The Chinese Antibacterial Drugs Market
- 1.5 Terminology Used in this Report

2. AN INTRODUCTION TO THE ANTIBACTERIAL DRUGS MARKET

- 2.1 Bacterial Infections and Antibacterial Drugs
 - 2.1.1 Gram-Positive and Gram-Negative Infections
 - 2.1.2 Treating Bacterial Infections
- 2.2 The Antibacterial Drugs Market 2011
 - 2.2.1 Leading Classes of Antibacterial Drug
 - 2.2.1.1 Cephalosporins
 - 2.2.1.2 Penicillins
 - 2.2.1.3 Fluoroquinolones
 - 2.2.1.4 Macrolides
 - 2.2.1.5 Carbapenems
- 2.3 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022
 - 2.3.1 Market Drivers 2012-2022
 - 2.3.2 Market Restraints 2012-2022
- 2.4 Leading Antibacterial Drug Manufacturers in 2011
 - 2.4.1 Company Comparison
 - 2.4.1.1 Broad Product Portfolios
 - 2.4.1.2 Regional Focus
 - 2.4.1.3 Future of the Antibacterial Drugs Industry

3. THE LEADING US BIG PHARMA ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022

- 3.1 Pfizer
 - 3.1.1 A Long History in Antibacterials

- 3.1.2 Antibacterial Product Portfolio
 - 3.1.2.1 Dalacin (Clindamycin)
 - 3.1.2.2 Sulperazon (Cefoperazone/Sulbactam)
 - 3.1.2.3 Tygacil (Tigecycline)
 - 3.1.2.4 Unasyn (Ampicillin/Sulbactam)
 - 3.1.2.5 Zithromax (Azithromycin)
 - 3.1.2.6 Zosyn (Piperacillin/Tazobactam)
 - 3.1.2.7 Zyvox (Linezolid)
- 3.1.3 Antibacterial Revenue 2011
- 3.1.4 Pipeline
 - 3.1.4.1 Pipeline 2007-2010
 - 3.1.4.2 PNU-100480 (Sutezolid)
- 3.1.5 Pfizer Antibacterials: SWOT Analysis
- 3.1.6 Antibacterial Revenue Forecast 2012-2022
- 3.2 Merck & Co.
 - 3.2.1 Antibacterial Product Portfolio
 - 3.2.1.1 Avelox (Moxifloxacin)
 - 3.2.1.2 Invanz (Ertapenem)
 - 3.2.1.3 Primaxin (Imipenem/Cilastatin)
 - 3.2.2 Antibacterial Revenue 2011
 - 3.2.3 Recent Licensing Deals
 - 3.2.4 Pipeline
 - 3.2.4.1 MK-3415A
 - 3.2.4.2 MK-7655
 - 3.2.5 Merck Antibacterials: SWOT Analysis
 - 3.2.6 Antibacterial Revenue Forecast 2012-2022
- 3.3 J&J
 - 3.3.1 Antibacterial Product Portfolio
 - 3.3.1.1 Doribax (Doripenem)
 - 3.3.1.2 Levaquin (Levofloxacin)
 - 3.3.2 Antibacterial Revenue 2011
 - 3.3.2.1 Patent Challenges
 - 3.3.3 Decreasing Investment in Antibacterials
 - 3.3.4 Pipeline: TMC207
 - 3.3.5 J&J Antibacterials: SWOT Analysis
 - 3.3.6 Antibacterial Revenue Forecast 2012-2022
- 3.4 Abbott Laboratories
 - 3.4.1 Antibacterial Product Portfolio
 - 3.4.1.1 Biaxin (Clarithromycin)

- 3.4.2 Antibacterial Revenue 2011
- 3.4.3 Abbott Antibacterials: SWOT Analysis
- 3.4.4 Antibacterial Revenue Forecast 2012-2022

4. THE LEADING EUROPEAN BIG PHARMA ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022

4.1 GSK

- 4.1.1 Antibacterial Product Portfolio
 - 4.1.1.1 Augmentin (Amoxicillin/Clavulanate)
 - 4.1.1.2 Bactroban (Mupirocin)
 - 4.1.1.3 Duac (Clindamycin/Benzoyl Peroxide)
 - 4.1.1.4 Fortum (Ceftazidime)
 - 4.1.1.5 Zinnat (Cefuroxime)
- 4.1.2 Antibacterial Revenue 2011
- 4.1.3 Antibacterials in the US
- 4.1.4 Pipeline
 - 4.1.4.1 GSK2251052
 - 4.1.4.2 GSK1322322
- 4.1.5 GSK Antibacterials: SWOT Analysis
- 4.1.6 Antibacterial Revenue Forecast 2012-2022

4.2 Novartis

- 4.2.1 Antibacterial Product Portfolio
 - 4.2.1.1 Ciprodex (Ciprofloxacin/Dexamethasone)
 - 4.2.1.2 Cubicin (Daptomycin)
 - 4.2.1.3 Moxeza (Moxifloxacin)
 - 4.2.1.4 TOBI Podhaler (Tobramycin Inhalation Powder)
 - 4.2.1.5 Vigamox (Moxifloxacin)
- 4.2.2 Antibacterial Revenue 2011
- 4.2.3 Entering and Exiting Licensing Agreements
- 4.2.4 Pipeline
 - 4.2.4.1 Finafloxacin
 - 4.2.4.2 LFF571
- 4.2.5 Novartis Antibacterials: SWOT Analysis
- 4.2.6 Antibacterial Revenue Forecast 2012-2022

4.3 Bayer

- 4.3.1 Antibacterial Product Portfolio
 - 4.3.1.1 Avelox (Moxifloxacin)
 - 4.3.1.2 Cipro (Ciprofloxacin)

- 4.3.2 Antibacterial Revenue 2011
- 4.3.3 Avelox Patent Challenges
- 4.3.4 Bayer and Trius Therapeutics
- 4.3.5 Pipeline
 - 4.3.5.1 Ciprofloxacin Inhale
 - 4.3.5.2 Amikacin Inhale
- 4.3.6 Bayer Antibacterials: SWOT Analysis
- 4.3.7 Antibacterial Revenue Forecast 2012-2022
- 4.4 AstraZeneca
 - 4.4.1 Antibacterial Product Portfolio
 - 4.4.1.1 Cubicin (Daptomycin)
 - 4.4.1.2 Merrem (Meropenem)
 - 4.4.1.3 Zinforo (Ceftaroline)
 - 4.4.2 Antibacterial Revenue 2011
 - 4.4.3 AstraZeneca Acquires Novexel
 - 4.4.4 Pipeline
 - 4.4.4.1 CAZ-AVI
 - 4.4.4.2 CEF104
 - 4.4.4.3 NXL103
 - 4.4.4.4 AZD5847
 - 4.4.5 AstraZeneca Antibacterials: SWOT Analysis
 - 4.4.6 Antibacterial Revenue Forecast 2012-2022
- 4.5 Roche
 - 4.5.1 Antibacterial Product Portfolio
 - 4.5.1.1 Rocephin (Ceftriaxone)
 - 4.5.2 Antibacterial Revenue 2011
 - 4.5.3 Roche Antibacterials: SWOT Analysis
 - 4.5.4 Antibacterial Revenue Forecast 2012-2022

5. THE LEADING JAPANESE ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022

- 5.1 Daiichi Sankyo
 - 5.1.1 Antibacterial Product Portfolio
 - 5.1.1.1 Cravit (Levofloxacin)
 - 5.1.2 Antibacterial Revenue 2011
 - 5.1.3 Lifecycle Management
 - 5.1.4 Pipeline
 - 5.1.5 Daiichi Sankyo Antibacterials: SWOT Analysis

- 5.1.6 Antibacterial Revenue Forecast 2012-2022
- 5.2 Shionogi & Co
 - 5.2.1 Antibacterial Product Portfolio
 - 5.2.1.1 Finibax (Doripenem)
 - 5.2.1.2 Flomox (Cefcapene)
 - 5.2.1.3 Shionogi Acquires Victory Pharma's Portfolio
 - 5.2.2 Antibacterial Revenue 2011
 - 5.2.3 Lifecycle Management
 - 5.2.4 Patent Challenges
 - 5.2.5 Pipeline
 - 5.2.5.1 S-649266
 - 5.2.6 Shionogi Antibacterials: SWOT Analysis
 - 5.2.7 Antibacterial Revenue Forecast 2012-2022
- 5.3 Meiji Seika Pharma
 - 5.3.1 Antibacterial Product Portfolio
 - 5.3.1.1 Meiact (Cefditoren)
 - 5.3.2 Antibacterial Revenue 2011
 - 5.3.3 Generic Competition
 - 5.3.4 ME1071
 - 5.3.5 Meiji Seika Pharma Antibacterials: SWOT Analysis
 - 5.3.6 Antibacterial Revenue Forecast 2012-2022
- 5.4 Astellas Pharma
 - 5.4.1 Antibacterial Product Portfolio
 - 5.4.1.1 Cefzon (Cefdinir)
 - 5.4.1.2 Geninax (Garenoxacin)
 - 5.4.2 Antibacterial Revenue 2011
 - 5.4.3 Astellas and Optimer Pharmaceuticals
 - 5.4.4 Astellas and Theravance
 - 5.4.5 Astellas Pharma Antibacterials: SWOT Analysis
 - 5.4.6 Antibacterial Revenue Forecast 2012-2022
- 5.5 Dainippon Sumitomo Pharma
 - 5.5.1 Meropen (Meropenem)
 - 5.5.2 Antibacterial Revenue 2011
 - 5.5.3 Licensing Deals
 - 5.5.4 Pipeline
 - 5.5.4.1 DSP-5990
 - 5.5.5 Dainippon Sumitomo Antibacterials: SWOT Analysis
 - 5.5.6 Antibacterial Revenue Forecast 2012-2022

6. THE LEADING SPECIALIST ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022

6.1 Cubist Pharmaceuticals

6.1.1 Antibacterial Product Portfolio

6.1.1.1 Cubicin (Daptomycin)

6.1.2 Antibacterial Revenue 2011

6.1.3 Lifecycle Management

6.1.4 Patent Challenges

6.1.5 Pipeline

6.1.5.1 CXA-201

6.1.5.2 CB-315

6.1.6 Cubist Antibacterials: SWOT Analysis

6.1.7 Antibacterial Revenue Forecast 2012-2022

6.2 Medicis

6.2.1 Antibacterial Product Portfolio

6.2.1.1 Solodyn (Minocycline)

6.2.1.2 Ziana (Clindamycin/Tretinoin)

6.2.2 Antibacterial Revenue 2011

6.2.3 Patent Extensions and Challenges

6.2.4 Pipeline

6.2.4.1 GW05

6.2.5 Medicis Antibacterials: SWOT Analysis

6.2.6 Antibacterial Revenue Forecast 2012-2022

6.3 Salix Pharmaceuticals

6.3.1 Xifaxan (Rifamixin)

6.3.2 Antibacterial Revenue 2011

6.3.3 Expanding Approved Indications

6.3.4 Salix Pharmaceuticals Antibacterials: SWOT Analysis

6.3.5 Antibacterial Revenue Forecast 2012-2022

6.4 ViroPharma

6.4.1 Vancocin (Vancomycin)

6.4.2 Antibacterial Revenue 2011

6.4.3 Generic Competition

6.4.4 Pipeline: VP20621

6.4.5 ViroPharma Antibacterials: SWOT Analysis

6.4.6 Antibacterial Revenue Forecast 2012-2022

6.5 Warner Chilcott

6.5.1 Doryx (Doxycycline)

- 6.5.2 Antibacterial Revenue 2011
- 6.5.3 Patent Challenges
- 6.5.4 Pipeline
- 6.5.5 Warner Chilcott Antibacterials: SWOT Analysis
- 6.5.6 Antibacterial Revenue Forecast 2012-2022

6.6 Allergan

- 6.6.1 Antibacterial Product Portfolio
 - 6.6.1.1 Zymar (Gatifloxacin)
 - 6.6.1.2 Zymaxid (Gatifloxacin)
- 6.6.2 Antibacterial Revenue 2011
- 6.6.3 Patent Challenges
- 6.6.4 Allergan Antibacterials: SWOT Analysis
- 6.6.5 Antibacterial Revenue Forecast 2012-2022

7. EMERGING ANTIBACTERIAL MANUFACTURERS

- 7.1 Pipeline Companies 2012
- 7.2 Durata Therapeutics
 - 7.2.1 Future Outlook
- 7.3 Optimer Pharmaceuticals
 - 7.3.1 Future Outlook
- 7.4 Rib-X Pharmaceuticals
 - 7.4.1 Future Outlook
- 7.5 Trius Therapeutics
 - 7.5.1 Future Outlook

8. CONCLUSIONS

- 8.1 Big Pharma Dominated the Antibacterials Market in 2011
- 8.2 The Rise of Generics
- 8.3 Small Companies Can Have a Big Impact on the Industry and Market to 2022

List Of Tables

LIST OF TABLES

Table 1.1 Currency Exchange Rates, 2011

Table 1.2 Common Abbreviations Used in this Report

Table 2.1 Classification of Common Infection-Causing Bacteria

Table 2.2 Antibacterial Drugs Market by Class, 2010-2011

Table 2.3 Selected Classes of Antibacterial Drug and their Mechanism of Action

Table 2.4 Cephalosporins: Role in the Antibacterial Drugs Market, 2011

Table 2.5 Penicillins: Role in the Antibacterial Drugs Market, 2011

Table 2.6 Fluoroquinolones: Role in the Antibacterial Drugs Market, 2011

Table 2.7 Macrolides: Role in the Antibacterial Drugs Market, 2011

Table 2.8 Carbapenems: Role in the Antibacterial Drugs Market, 2011

Table 2.9 Antibacterial Drugs: Overall World Market and Submarket Forecasting, 2011, 2016 & 2022

Table 2.10 Top 20 Antibacterial Manufacturers by Revenue, 2011

Table 2.11 Antibacterial Revenue as a Share of Pharmaceutical Revenue, 2011

Table 3.1 Pfizer: Key Facts, 2012

Table 3.2 Pfizer: Antibacterial Revenue, 2009-2011

Table 3.3 Pfizer: Antibacterial SWOT Analysis, 2012-2022

Table 3.4 Pfizer: Antibacterial Revenue Forecast, 2011-2022

Table 3.5 Merck & Co: Key Facts, 2012

Table 3.6 Merck & Co: Antibacterial Revenue, 2009-2011

Table 3.7 Merck & Co: Antibacterial SWOT Analysis, 2012-2022

Table 3.8 Merck & Co: Antibacterial Revenue Forecast, 2011-2022

Table 3.9 J&J: Key Facts, 2012

Table 3.10 J&J: Antibacterial Revenue, 2009-2011

Table 3.11 J&J: Antibacterial SWOT Analysis, 2012-2022

Table 3.12 J&J: Antibacterial Revenue Forecast, 2011-2022

Table 3.13 Abbott: Key Facts, 2012

Table 3.14 Abbott: Antibacterial SWOT Analysis, 2012-2022

Table 3.15 Abbott: Antibacterial Revenue Forecast, 2011-2022

Table 4.1 GSK: Key Facts, 2012

Table 4.2 GSK: Antibacterial Revenue, 2010-2011

Table 4.3 Augmentin, Revenue by Region, 2011

Table 4.4 GSK: Antibacterial Drug Pipeline, 2012

Table 4.5 GSK: Antibacterial SWOT Analysis, 2012-2022

Table 4.6 GSK: Antibacterial Revenue Forecast, 2011-2022

Table 4.7 Novartis: Key Facts, 2012

Table 4.8 Novartis: Antibacterial Revenue, 2009-2011

Table 4.9 Novartis: Antibacterial SWOT Analysis, 2012-2022

Table 4.10 Novartis: Antibacterial Revenue Forecast, 2011-2022

Table 4.11 Bayer: Key Facts, 2012

Table 4.12 Bayer: Antibacterial Revenue, 2009-2011

Table 4.13 Avelox: Patent Expiries by Country, 2013-2015

Table 4.14 Bayer: Antibacterial SWOT Analysis, 2012-2022

Table 4.15 Bayer: Antibacterial Revenue Forecast, 2011-2022

Table 4.16 AstraZeneca: Key Facts, 2012

Table 4.17 AstraZeneca: Antibacterial Revenue, 2008-2011

Table 4.18 AstraZeneca: Antibacterial SWOT Analysis, 2012-2022

Table 4.19 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022

Table 4.20 Roche: Key Facts, 2012

Table 4.21 Roche: Antibacterial Revenue, Q1-Q4 2011

Table 4.22 Roche: Antibacterial Revenue by Region, Q1 2012

Table 4.23 Roche: Antibacterial SWOT Analysis, 2012-2022

Table 4.24 Roche: Antibacterial Revenue Forecast, 2011-2022

Table 5.1 Daiichi Sankyo: Key Facts, 2012

Table 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011

Table 5.3 Daiichi Sankyo: Antibacterial SWOT Analysis, 2012-2022

Table 5.4 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022

Table 5.5 Shionogi: Key Facts, 2012

Table 5.6 Shionogi: Antibacterial SWOT Analysis, 2012-2022

Table 5.7 Shionogi: Antibacterial Revenue Forecast, 2011-2022

Table 5.8 Meiji Seika Pharma: Key Facts, 2012

Table 5.9 Meiji Seika Pharma: Antibacterial SWOT Analysis, 2012-2022

Table 5.10 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022

Table 5.11 Astellas Pharma: Key Facts, 2012

Table 5.12 Astellas Pharma: Leading Antibacterial Drug Revenue, FY 2007-2011

Table 5.13 Astellas Pharma: Antibacterial SWOT Analysis, 2012-2022

Table 5.14 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022

Table 5.15 Dainippon Sumitomo: Key Facts, 2012

Table 5.16 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011

Table 5.17 Dainippon Sumitomo: Antibacterial SWOT Analysis, 2012-2022

Table 5.18 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022

Table 6.1 Cubist Pharmaceuticals: Key Facts, 2012

Table 6.2 Cubist: Antibacterial Revenue, 2008-2011

Table 6.3 Cubicin: International Revenue Payments, 2008-2011

Table 6.4 Cubist: Antibacterial SWOT Analysis, 2012-2022

Table 6.5 Cubist: Antibacterial Revenue Forecast, 2011-2022

Table 6.6 Medicis: Key Facts, 2012

Table 6.7 Medicis: Antibacterial Revenue, 2009-2011

Table 6.8 Medicis: Antibacterial SWOT Analysis, 2012-2022

Table 6.9 Medicis: Antibacterial Revenue Forecast, 2011-2022

Table 6.10 Salix Pharmaceuticals: Key Facts, 2012

Table 6.11 Salix: Antibacterial Revenue, 2009-2011

Table 6.12 Salix: Antibacterial SWOT Analysis, 2012-2022

Table 6.13 Salix: Antibacterial Revenue Forecast, 2011-2022

Table 6.14 ViroPharma: Key Facts, 2012

Table 6.15 ViroPharma: Antibacterial Revenue, 2009-2011

Table 6.16 ViroPharma: Antibacterial SWOT Analysis, 2012-2022

Table 6.17 ViroPharma: Antibacterial Revenue Forecast, 2011-2022

Table 6.18 Warner Chilcott: Key Facts, 2012

Table 6.19 Warner Chilcott: Antibacterial SWOT Analysis, 2012-2022

Table 6.20 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022

Table 6.21 Allergan: Key Facts, 2012

Table 6.22 Allergan: Antibacterial SWOT Analysis, 2012-2022

Table 6.23 Allergan: Antibacterial Revenue Forecast, 2011-2022

Table 7.1 Emerging Companies in the Antibacterial Drugs Market, 2012

Table 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011

List Of Figures

LIST OF FIGURES

- Figure 2.1 Antibacterial Drugs Market by Class, 2010-2011
- Figure 2.2 Antibacterial Drugs: Overall Market Forecast, 2011, 2016 & 2022
- Figure 2.3 Antibacterial Drugs Market: Drivers and Restraints, 2012-2022
- Figure 2.4 Top 20 Antibacterial Manufacturers by Revenue, 2011
- Figure 2.5 Antibacterial Drug Market Entry, 1935-2004
- Figure 3.1 Pfizer: Antibacterial Market History, 1944-2009
- Figure 3.2 Pfizer: Antibacterial Revenue Shares, 2011
- Figure 3.3 Pfizer: Antibacterial Revenue Forecast, 2011-2022
- Figure 3.4 Pfizer: Antibacterial Market Share, 2011-2022
- Figure 3.5 Merck & Co: Antibacterial Revenue, 2009-2011
- Figure 3.6 Merck & Co: Antibacterial Revenue Forecast, 2011-2022
- Figure 3.7 Merck & Co: Antibacterial Market Share, 2011-2022
- Figure 3.8 J&J: Antibacterial Revenue, 2009-2011
- Figure 3.9 J&J: Antibacterial Revenue Forecast, 2011-2022
- Figure 3.10 J&J: Antibacterial Market Share, 2011-2022
- Figure 3.11 Abbott: Antibacterial Revenue Forecast, 2011-2022
- Figure 3.12 Abbott: Antibacterial Market Share, 2011-2022
- Figure 4.1 GSK: Antibacterial Revenue Shares, 2011
- Figure 4.2 Augmentin, Revenue Shares by Region, 2011
- Figure 4.3 GSK: Antibacterial Revenue Forecast, 2011-2022
- Figure 4.4 GSK: Antibacterial Market Share, 2011-2022
- Figure 4.5 Novartis: Antibacterial Revenue Shares, 2011
- Figure 4.6 Novartis: Antibacterial Revenue Forecast, 2011-2022
- Figure 4.7 Novartis: Antibacterial Market Share, 2011-2022
- Figure 4.8 Bayer: Antibacterial Revenue, 2009-2011
- Figure 4.9 Bayer: Antibacterial Revenue Forecast, 2011-2022
- Figure 4.10 Bayer: Antibacterial Market Share, 2011-2022
- Figure 4.11 AstraZeneca: Antibacterial Sales Revenue, 2008-2011
- Figure 4.12 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022
- Figure 4.13 AstraZeneca: Antibacterial Market Share, 2011-2022
- Figure 4.14 Roche: Antibacterial Revenue Shares, Q1-Q4 2011
- Figure 4.15 Roche: Antibacterial Revenue Shares by Region, Q1 2012
- Figure 4.16 Roche: Antibacterial Revenue Forecast, 2011-2022
- Figure 4.17 Roche: Antibacterial Market Share, 2011-2022
- Figure 5.1 Daiichi Sankyo: Antibacterial Market History, 1937-1993

- Figure 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011
- Figure 5.3 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022
- Figure 5.4 Daiichi Sankyo: Antibacterial Market Share, 2011-2022
- Figure 5.5 Shionogi: Antibacterial Revenue Forecast, 2011-2022
- Figure 5.6 Shionogi: Antibacterial Market Share, 2011-2022
- Figure 5.7 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022
- Figure 5.8 Meiji Seika Pharma: Antibacterial Market Share, 2011-2022
- Figure 5.9 Astellas Pharma: Leading Antibacterial Drug Revenues, FY 2007-2011
- Figure 5.10 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022
- Figure 5.11 Astellas Pharma: Antibacterial Market Share, 2011-2022
- Figure 5.12 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011
- Figure 5.13 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022
- Figure 5.14 Dainippon Sumitomo: Antibacterial Market Share, 2011-2022
- Figure 6.1 Cubist: Antibacterial Revenue, 2008-2011
- Figure 6.2 Cubicin: International Revenue Payments, 2008-2011
- Figure 6.3 Cubist: Antibacterial Market Share, 2011-2022
- Figure 6.4 Cubist: Antibacterial Revenue Forecast, 2011-2022
- Figure 6.5 Medicis: Antibacterial Revenue, 2009-2011
- Figure 6.6 Medicis: Antibacterial Revenue Forecast, 2011-2022
- Figure 6.7 Medicis: Antibacterial Market Share, 2011-2022
- Figure 6.8 Salix: Antibacterial Revenue, 2009-2011
- Figure 6.9 Salix: Antibacterial Revenue Forecast, 2011-2022
- Figure 6.10 Salix: Antibacterial Market Share, 2011-2022
- Figure 6.11 ViroPharma: Antibacterial Revenue, 2009-2011
- Figure 6.12 ViroPharma: Antibacterial Revenue Forecast, 2011-2022
- Figure 6.13 ViroPharma: Antibacterial Market Share, 2011-2022
- Figure 6.14 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022
- Figure 6.15 Warner Chilcott: Antibacterial Market Share, 2011-2022
- Figure 6.16 Allergan: Antibacterial Revenue Forecast, 2011-2022
- Figure 6.17 Allergan: Antibacterial Market Share, 2011-2022
- Figure 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011

COMPANIES LISTED

Abbott Laboratories
Adolor (part of Cubist)
Advanced Life Sciences
AiCuris
Akorn

Alcon Laboratories (a division of Novartis)
Alfa Wassermann
Allergan
Anacor Pharmaceuticals
Apotex
Astellas Pharma
AstraZeneca
Barr Laboratories (part of Teva)
Basilea Pharmaceutica
Bayer
BioRelix
Biovail Laboratories (part of Valeant Pharmaceuticals)
Bristol-Myers Squibb
Calixa Therapeutics (part of Cubist)
Cempra Pharmaceuticals
Chiron (now part of Novartis)
Cornerstone Therapeutics
Cubist Pharmaceuticals
Daiichi Sankyo
Daiichi Sankyo Pharmaceutical (Beijing)
Daiichi Sankyo Pharmaceutical (Shanghai)
Dainippon Pharmaceutical (part of Dainippon Sumitomo)
Dainippon Sumitomo Pharma
DAVA Pharmaceuticals
Department of Health and Human Services' Biomedical Advanced Research and
Development Authority (BARDA) [US]
Dr Reddy's Laboratories
Durata Therapeutics
Eli Lilly
EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
European Medicines Agency (EMA)
Food and Drug Administration (FDA) [US]
Forest Laboratories
Fujisawa Pharmaceutical (part of Astellas Pharma)
Furiex Pharmaceuticals
Genzyme (part of Sanofi)
Graceway Pharmaceuticals
GSK
Heritage Pharmaceuticals

Hikma Farmaceutica
Hi-Tech Pharmacal
Hospira
Impax Laboratories
Innovative Medicines Initiative [EU]
Itochu Chemical Frontier
Janssen Pharmaceutica (a subsidiary of J&J)
Japan Patent Office (JPO)
Johnson & Johnson (J&J)
Kyorin Pharmaceutical
Lupin
Massachusetts Biologic Laboratories
Mayne Pharma
Medarex (part of Bristol-Myers Squibb)
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Medicis
Medison Pharma
Meiji Holdings (parent company of Meiji Seika Pharma)
Meiji Seika Pharma
Merck & Co.
MerLion Pharmaceuticals
Ministry of Health, Labor and Welfare (MHLW)
Mylan
Mylan Seiyaku (a subsidiary of Mylan)
Nabriva Therapeutics
Nanotherapeutics
National Institute of Allergy and Infectious Diseases (NIAID) [US]
Nektar Therapeutics
Nestl?
NeuTec Pharma (part of Novartis, now closed)
Nichi-Iko Pharmaceutical
Nipro Pharma
Novartis
Novexel (part of AstraZeneca)
Optimer Biotechnology (a subsidiary of Optimer)
Optimer Pharmaceuticals
Ortho-McNeil Pharmaceutical (a subsidiary of J&J)
Paratek Pharmaceuticals
Patent and Trademark Office [US]

Peninsula Pharmaceuticals (part of J&J)
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmacia (part of Pfizer)
Pliva (part of Teva)
Proctor & Gamble (P&G)
Protez Pharmaceuticals (part of Novartis, now closed)
Ranbaxy (part of Daiichi Sankyo)
Rib-X Pharmaceuticals
Roche
Rutgers University [US]
Salix Pharmaceuticals
Sandoz (a division of Novartis)
Sanofi
Sawai Pharmaceutical
Schering-Plough (part of Merck & Co)
Scottish Medicines Consortium (SMC)
Senju Pharmaceutical
Sequella
Shantou Meiji Pharmaceuticals (a subsidiary of Meiji Seika Pharma)
Shionogi & Co
Sincere Pharmaceutical Group
State Food and Drug Administration (SFDA) [China]
Stiefel Laboratories (part of GSK)
Strides Arcolab
Sumitomo Pharmaceutical (part of Dainippon Sumitomo)
Sunovion Pharmaceuticals
TaiGen Biotechnology
Taisho Pharmaceutical
Taiyo Yakuin (Taiyo Pharmaceutical Industry)
Takeda Pharmaceutical
TB Alliance
Tedec-Meiji Farma (a subsidiary of Meiji Seika Pharma)
Tetraphase Pharmaceuticals
Teva Pharmaceutical Industries
The Medicines Company
Theravance
Tibotec Pharmaceuticals (part of Janssen Pharmaceutica)
Towa Pharmaceutical

Toyama Chemical
Trius Therapeutics
Upjohn (part of Pfizer)
Victory Pharma
Vicuron Pharmaceuticals (part of Durata)
ViroPharma
Wakunaga Pharmaceutical
Warner Chilcott
Warner Lambert (part of Pfizer)
Watson Pharmaceuticals
Women First HealthCare
World Health Organization (WHO)
Wyeth Pharmaceuticals (part of Pfizer)
Yale University [US]
Yamanouchi Pharmaceutical (part of Astellas)
Zuellig Pharma

I would like to order

Product name: Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022

Product link: <https://marketpublishers.com/r/PB44E23F109EN.html>

Price: US\$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB44E23F109EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970